2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.23 (Poster) Plasma cell-free RNA PD-L1 or Tissue PD-L1 Protein Expression and Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer

PP01.23 (Poster) Plasma cell-free RNA PD-L1 or Tissue PD-L1 Protein Expression and Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer

Back to course

Pdf Summary

Researchers from the Division of Hematology/Oncology at the Brody School of Medicine at East Carolina University conducted a study to investigate the association between plasma cell-free RNA PD-L1 expression and tissue PD-L1 protein expression with immunotherapy outcomes in advanced non-small cell lung cancer (NSCLC). The study included 53 patients with metastatic NSCLC who were treated with first-line immunotherapy regimens. The patients were divided into three cohorts based on their plasma cfRNA PD-L1 and tissue PD-L1 protein expression: plasma PD-L1 positive, tissue PD-L1 positive, and PD-L1 negative.<br /><br />The researchers compared the overall survival (OS) of the three patient cohorts. They found that positive plasma cfRNA PD-L1 expression was associated with favorable outcomes in patients treated with first-line immunotherapy regimens. The median OS for patients with positive plasma cfRNA PD-L1 expression was 15 months, compared to 8 months for patients lacking PD-L1 expression. The three-year OS rate was 30% for patients with positive plasma cfRNA PD-L1 expression, compared to 15% for patients lacking PD-L1 expression.<br /><br />The study also showed that positive plasma cfRNA PD-L1 expression or positive tissue PD-L1 protein expression were associated with similar survival outcome benefits. In the positive plasma PD-L1 patients, there was no difference in survival outcomes based on tissue PD-L1 expression. These findings suggest that plasma cfRNA PD-L1 expression could be used as a potential biomarker for predicting immunotherapy outcomes in advanced NSCLC patients.<br /><br />In conclusion, the study found that positive plasma cfRNA PD-L1 expression was associated with better survival outcomes in patients with advanced NSCLC treated with immunotherapy. The researchers also found a correlation between positive plasma cfRNA PD-L1 expression and positive tissue PD-L1 protein expression. This study highlights the potential of using plasma cfRNA PD-L1 as a non-invasive biomarker for predicting immunotherapy outcomes in NSCLC patients. Further research is needed to validate these findings and to explore the clinical implications of plasma cfRNA PD-L1 testing in the management of NSCLC.

Asset Subtitle

Paul Walker

Keywords

Division of Hematology/Oncology

Brody School of Medicine

East Carolina University

plasma cell-free RNA

PD-L1 expression

tissue PD-L1 protein expression

immunotherapy outcomes

advanced non-small cell lung cancer

metastatic NSCLC

first-line immunotherapy regimens